In their experiments to test this idea, the researchers studied mice that produce many of the characteristic pathologies of fragile X in humans due to a loss of the FMRP gene. The critical test, though, was when they also created double mutant mice that lacked both the FMRP gene and had a 50% reduction in mGluR5. They chose only to reduce the activity of the metabotropic glutamate receptor gene, rather than eliminate it, in order to reflect what might be achieved using drug treatment for fragile X in humans.

Their tests on the double mutant mice revealed that the mGluR5 gene reduction greatly alleviated many abnormalities produced by loss of FMRP. The double mutant mice showed a rescue of abnormalities in brain structure and function, brain protein synthesis, memory, and body growth.

For example, loss of the FMRP gene produces overgrowth of the connections among neurons called dendritic spines. However, the additional 50% reduction in mGluR5 gene produced mice with completely normal spine density.

The double mutants also showed substantial reduction in epileptic seizures caused by lack of FMRP, found the researchers.

They concluded that “it is remarkable that by reducing mGluR5 gene dosage by 50%, we were able to bring multiple, widely varied fragile X phenotypes significantly closer to normal.”

They also concluded that “These findings have major therapeutic implications for fragile X syndrome and autism.”

The researchers include Gul Dolen, Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA, and Department of Neuroscience, Brown Medical School and the Division of Biology and Medicine, Providence, RI, USA; Emily Osterweil, Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA; B.S. Shankaranarayana Rao, Department of Neurophysiology, National Institute of Mental Health and Neuroscience, Bangalore, India; Gordon B. Smith, Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA; Benjamin D. Auerbach, Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA; Sumantra Chattarji, National Center for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, India; and Mark F. Bear, Howard Hughes Medical Institute, The Picower Institute for Learning and Memory, Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA.